-
公开(公告)号：US20180318387A1
公开(公告)日：2018-11-08
申请号：US16010227
申请日：2018-06-15
申请人： CardioVax, LLC
IPC分类号： A61K38/17 , G01N33/564 , A61K38/51 , A61K39/395 , C07K16/18
CPC分类号： A61K38/1709 , A61K38/51 , A61K39/0005 , A61K39/3955 , C07K16/18 , C07K2317/21 , C07K2317/56 , C12Y406/01001 , G01N33/564 , G01N2333/775 , G01N2800/104 , Y02A50/471
摘要： Described herein are peptides and antibodies for prevention and/or therapeutic treatment of mammals, including humans, against systemic lupus erythematosus, as well as diagnosing the presence or absence of antibodies related to increased or decreased risk of developing SLE and/or to disease grading, staging, and/or prognosis.
-
公开(公告)号：US20170340702A1
公开(公告)日：2017-11-30
申请号：US15610527
申请日：2017-05-31
申请人： CardioVax, LLC
发明人： Mark Carvlin , Jan Nilsson , Stacey Ruiz
IPC分类号： A61K38/17 , A61K38/51 , G01N33/564 , A61K39/395 , C07K16/18
CPC分类号： A61K38/1709 , A61K38/51 , A61K39/0008 , A61K39/3955 , A61K2039/55505 , A61K2039/572 , A61K2039/6037 , A61K2039/6081 , A61P37/00 , C07K16/18 , C07K2317/21 , C07K2317/56 , C12Y406/01001 , G01N33/564 , G01N2333/775 , G01N2800/104 , Y02A50/471
摘要： Described herein are peptides and antibodies for prevention and/or therapeutic treatment of mammals, including humans, against systemic lupus erythematosus, as well as diagnosing the presence or absence of antibodies related to increased or decreased risk of developing SLE and/or to disease grading, staging, and/or prognosis.
-
公开(公告)号：US09821056B2
公开(公告)日：2017-11-21
申请号：US15264890
申请日：2016-09-14
申请人： Inventprise, LLC
发明人： Subhash V. Kapre
CPC分类号： A61K39/39 , A61K39/099 , A61K2039/55 , A61K2039/55544 , A61K2039/55572 , C12Y406/01001
摘要： The invention is directed to a method for the production of a pertussis vaccine and, in particular, a detoxified pertussis vaccine comprising detoxified pertussis toxin (PT), detoxified pertussis lipopolysaccharide (P-LPS), and detoxified pertussis adenylate cyclase toxin (P-ACT). The invention is also directed to the manufacture of a vaccine or the invention and methods for the administration of a detoxified vaccine to patients.
-
公开(公告)号：US20160376561A1
公开(公告)日：2016-12-29
申请号：US15263257
申请日：2016-09-12
发明人： Caleb Bell, III , Alexey Bazarov
CPC分类号： C12N5/166 , C12N1/00 , C12N5/00 , C12N5/16 , C12N9/88 , C12N15/02 , C12N15/03 , C12Q1/6897 , C12Y406/01001
摘要： The present invention is directed generally to eukaryotic host cells comprising artificial endosymbionts and methods of introducing artificial endosymbionts into eukaryotic host cells. The invention provides artificial endosymbionts that introduce a phenotype to host cells that is maintained in daughter cells. The invention additionally provides eukaryotic host cells containing magnetotactic bacteria.
-
5.发明授权Genetically detoxified pertussis vaccine that maintains intrinsic adjuvant activity 有权基因解毒的百日咳疫苗维持内在的佐剂活性公开(公告)号：US09452213B2
公开(公告)日：2016-09-27
申请号：US14800126
申请日：2015-07-15
申请人： Subhash V. Kapre
发明人： Subhash V. Kapre
CPC分类号： A61K39/39 , A61K39/099 , A61K2039/55 , A61K2039/55544 , A61K2039/55572 , C12Y406/01001
摘要： The invention is directed to a method for the production of a pertussis vaccine and, in particular, a detoxified pertussis vaccine comprising detoxified pertussis toxin (PT), detoxified pertussis lipopolysaccharide (P-LPS), and detoxified pertussis adenylate cyclase toxin (P-ACT). The invention is also directed to the manufacture of a vaccine or the invention and methods for the administration of a detoxified vaccine to patients.
摘要翻译： 本发明涉及生产百日咳疫苗的方法，特别是包括解毒的百日咳毒素（PT），解毒的百日咳脂多糖（P-LPS）和解毒的百日咳腺苷酸环化酶毒素（P-ACT）的解毒百日咳疫苗 ）。 本发明还涉及制造疫苗或本发明以及向患者施用解毒疫苗的方法。
-
公开(公告)号：US09370564B2
公开(公告)日：2016-06-21
申请号：US13169605
申请日：2011-06-27
申请人： Claude LeClerc , Pierre Guermonprez , Daniel Ladant , Nicole Guiso , Nadia Khelef , Cecile Bauche , Catherine Fayolle , Mohammed El-Azami El-Idrissi
发明人： Claude LeClerc , Pierre Guermonprez , Daniel Ladant , Nicole Guiso , Nadia Khelef , Cecile Bauche , Catherine Fayolle , Mohammed El-Azami El-Idrissi
IPC分类号： A61K39/385 , C07K14/235 , A61K47/48 , A61K39/00
CPC分类号： A61K39/099 , A61K39/385 , A61K47/646 , A61K2039/57 , A61K2039/6037 , C12N9/88 , C12N15/85 , C12Y406/01001 , Y02A50/466
摘要： The invention relates to a novel use of a Bordetella adenylcyclase toxin in the manufacturing of vectors for targeting in vivo a molecule of interest, specifically to CD11b expressing cells. The invention also relates to an immunogenic composition that primes immune responses, to pharmaceutical compositions and to a new vector for molecule delivery to CD11b expressing cells.
摘要翻译： 本发明涉及博德特氏子腺苷环化酶毒素在制备用于靶向靶分子的载体中，特别是靶向CD11b表达细胞的新颖应用。 本发明还涉及引发免疫应答的免疫原性组合物，药物组合物和用于向CD11b表达细胞递送分子的新载体。
-
公开(公告)号：US09085764B2
公开(公告)日：2015-07-21
申请号：US14582823
申请日：2014-12-24
发明人： Caleb Bell, III , Alexey Bazarov
CPC分类号： C12N5/166 , C12N1/00 , C12N5/00 , C12N5/16 , C12N9/88 , C12N15/02 , C12N15/03 , C12Q1/6897 , C12Y406/01001
摘要： The present invention is directed generally to eukaryotic host cells comprising artificial endosymbionts and methods of introducing artificial endosymbionts into eukaryotic host cells. The invention provides artificial endosymbionts that introduce a phenotype to host cells that is maintained in daughter cells. The invention additionally provides eukaryotic host cells containing magnetotactic bacteria.
-
公开(公告)号：US20150152391A1
公开(公告)日：2015-06-04
申请号：US14582823
申请日：2014-12-24
发明人： Caleb Bell, III , Alexy Bazarov
IPC分类号： C12N5/16
CPC分类号： C12N5/166 , C12N1/00 , C12N5/00 , C12N5/16 , C12N9/88 , C12N15/02 , C12N15/03 , C12Q1/6897 , C12Y406/01001
摘要： The present invention is directed generally to eukaryotic host cells comprising artificial endosymbionts and methods of introducing artificial endosymbionts into eukaryotic host cells. The invention provides artificial endosymbionts that introduce a phenotype to host cells that is maintained in daughter cells. The invention additionally provides eukaryotic host cells containing magnetotactic bacteria.
-
9.发明申请RECOMBINANT ADENYLATE CYCLASE TOXIN OF BORDETELLA INDUCES T CELL RESPONSES AGAINST TUMORAL ANTIGENS 审中-公开BORDETELLA的重组腺苷酸环化酶诱导针对肿瘤抗原的T细胞应答公开(公告)号：US20100310594A1
公开(公告)日：2010-12-09
申请号：US12731196
申请日：2010-03-25
申请人： Gilles Dadaglio , Claude Leclerc , Daniel Ladant , Benoit Van Den Eynde , Sandra Morel , Cecile Bauche
发明人： Gilles Dadaglio , Claude Leclerc , Daniel Ladant , Benoit Van Den Eynde , Sandra Morel , Cecile Bauche
CPC分类号： F16C33/7886 , A61K38/164 , A61K39/0011 , A61K39/099 , A61K39/39 , A61K47/6415 , A61K47/646 , A61K2039/6037 , A61K2039/6068 , C12N9/88 , C12Y406/01001 , F16C25/083
摘要： An immunogenic composition comprising a recombinant protein comprising a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen is provided as a cancer treatment. Methods of treatment with this immunogenic composition are also provided. In an embodiment, the therapeutic composition is a treatment for melanoma, and comprises epitopes from the HLA*0201 epitope. These epitopes include Tyr or GnT-V, and are present in the recombinant proteins CyaA-E5-Tyr and CyaA-E5-GnT-V.
摘要翻译： 作为癌症治疗，提供了含有包含Bordetella CyaA或其片段的重组蛋白质和对应于肿瘤抗原的肽的免疫原性组合物。 还提供了用该免疫原性组合物治疗的方法。 在一个实施方案中，治疗组合物是黑素瘤的治疗，并且包含来自HLA * 0201表位的表位。 这些表位包括Tyr或GnT-V，并且存在于重组蛋白CyaA-E5-Tyr和CyaA-E5-GnT-V中。
-
10.发明申请Pharmaceutical and Therapeutic Applications Relating to a Type 9 Adenylyl Cyclase Polymorphism in Asthma and Reversible Bronchial Obstruction 有权关于哮喘和可逆性支气管阻塞的9型腺苷酰环化酶多态性的药物和治疗应用公开(公告)号：US20090149376A1
公开(公告)日：2009-06-11
申请号：US11912205
申请日：2006-04-24
申请人： Stephen B. Liggett
发明人： Stephen B. Liggett
IPC分类号： A61K31/7088 , G01N33/53 , C12Q1/68 , A61P11/06
CPC分类号： C12Q1/6883 , C12N9/88 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172 , C12Y406/01001
摘要： A pharmaceutical composition comprising an expression product of a Type Nine adenylyl cyclase gene polymorphism, along with a suitable physiological carrier, are provided. In addition, methods related to treating patients having asthma or a reversible bronchial obstruction, kits for determining the responsiveness of an individual to treatment regimens, and assays for screening pharmaceutical for efficacy in treatment are also provided.
摘要翻译： 提供了包含九腺苷酸环化酶基因多态性的表达产物以及合适的生理载体的药物组合物。 此外，还提供了与治疗患有哮喘或可逆性支气管阻塞的患者相关的方法，用于确定个体对治疗方案的反应性的试剂盒，以及用于筛选药物治疗功效的测定法。
-
-
-
-
-
-
-
-
-
搜索结果
83 条记录 (耗时 0.036 秒)
